Glaxo and Galapagos Ink Anti-Infective Development Deal
 
GlaxoSmithKline and Galapagos this week said that they have entered into a multi-year, strategic alliance to develop novel anti-infective drug candidates.
 
GSK will participate in the alliance through its Infectious Diseases Center of Excellence for Drug Discovery. Under the terms of the agreement, Galapagos will grant GSK options to license product candidates that are directed against up to six anti-infective discovery targets. 
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.